Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). Inhibiting the entire receptor complex prevents IL-6 ...

Elevated interleukin (IL)-17 levels are increasingly ... in the muscle fibers before and after treatment with IL-6 antibodies.” MHC class I expression is a characteristic histopathological ...

The report delivers a comprehensive analysis of global biologics sales. Covering cancer antibodies, non-TNF inflammatory mAbs, biosimilars, gene therapy, RNA-based drugs, and more, the report provides ...